Solid BiosciencesSLDB
Market Cap: $303M
About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Employees: 88
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
45% more funds holding
Funds holding: 55 [Q1] → 80 (+25) [Q2]
5.23% more ownership
Funds ownership: 92.72% [Q1] → 97.96% (+5.23%) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
54% less capital invested
Capital invested by funds: $466M [Q1] → $213M (-$253M) [Q2]
61% less call options, than puts
Call options by funds: $51K | Put options by funds: $131K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Barclays Gena Wang 36% 1-year accuracy 9 / 25 met price target | 91%upside $15 | Overweight Maintained | 14 Aug 2024 |
HC Wainwright & Co. Arthur He 38% 1-year accuracy 12 / 32 met price target | 104%upside $16 | Buy Reiterated | 14 Aug 2024 |
JP Morgan Anupam Rama 44% 1-year accuracy 26 / 59 met price target | 91%upside $15 | Overweight Upgraded | 15 Jul 2024 |
Leerink Partners Joseph Schwartz 50% 1-year accuracy 3 / 6 met price target | 53%upside $12 | Outperform Upgraded | 24 Jun 2024 |